Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients

por Jamroz-Wiśniewska, Anna, Zajdel, Radosław, Słowik, Agnieszka, Marona, Monika, Wnuk, Marcin, Adamczyk-Sowa, Monika, Adamczyk, Bożena, Lasek-Bal, Anetta, Puz, Przemysław, Stęposz, Arkadiusz, Krzystanek, Ewa, Patalong-Ogiewa, Maja, Pokryszko-Dragan, Anna, Budrewicz, Sławomir, Koziarska, Dorota, Karbicka, Anna, Wawrzyniak, Sławomir, Fryze, Waldemar, Furtak-Niczyporuk, Marzena, Rejdak, Konrad
Publicado 2021

Care-based community communication, capacity, and agency during the COVID-19 pandemic: Evidence from the Complexo da Maré Favela, Brazil

por Poets, Desiree, Grimes, Catherine, Stephenson, Max, Moayerian, Neda, Todd, Molly
Publicado 2023

Serum Levels of CXCL13 Are Associated With Teriflunomide Response in Patients With Multiple Sclerosis

por Fissolo, Nicolás, Pappolla, Agustin, Rio, Jordi, Villar, Luisa M., Perez-Hoyos, Santiago, Sanchez, Alex, Gutierrez, Lucía, Montalban, Xavier, Comabella, Manuel
Publicado 2022

Genetic Variant HLA-DRB1*0403 and Therapeutic Response to Disease-Modifying Therapies in Multiple Sclerosis: A Case-Control Study

por Gomez-Gaitan, Esteban Alejandro, Garcia-Ortega, Yessica Eleanet, Saldaña-Cruz, Ana Miriam, Contreras-Haro, Betsabe, Gamez-Nava, Jorge Ivan, Perez-Guerrero, Emilio Edsaul, Nava-Valdivia, Cesar Arturo, Gallardo-Moya, Sergio, Martinez-Hernandez, Alejandra, Gonzalez Lopez, Laura, Rios-Gonzalez, Blanca Esthela, Marquez-Pedroza, Jazmin, Mendez-del Villar, Miriam, Esparza-Guerrero, Yussef, Villagomez-Vega, Alejandra, Macias Islas, Miguel Angel
Publicado 2023

Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod

por Ziemssen, Tjalf, Kern, Raimar, Cornelissen, Christian
Publicado 2016